Nektar Therapeutics (FRA:ITH) EV-to-Revenue : 1.62 (As of May. 20, 2024)

View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nektar Therapeutics's enterprise value is €135.36 Mil. Nektar Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €83.36 Mil. Therefore, Nektar Therapeutics's EV-to-Revenue for today is 1.62.

The historical rank and industry rank for Nektar Therapeutics's EV-to-Revenue or its related term are showing as below:

FRA:ITH' s EV-to-Revenue Range Over the Past 10 Years
Min: -2.59 Med: 10.07 Max: 55.59
Current: 1.63

During the past 13 years, the highest EV-to-Revenue of Nektar Therapeutics was 55.59. The lowest was -2.59. And the median was 10.07.

FRA:ITH's EV-to-Revenue is ranked better than
83.59% of 1042 companies
in the Biotechnology industry
Industry Median: 8.155 vs FRA:ITH: 1.63

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-20), Nektar Therapeutics's stock price is €1.59. Nektar Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.44. Therefore, Nektar Therapeutics's PS Ratio for today is 3.65.

Nektar Therapeutics EV-to-Revenue Historical Data

The historical data trend for Nektar Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics EV-to-Revenue Chart

Nektar Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

25.25

14.06

18.79

0.57

-0.86

Nektar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															-2.20	-2.00	-1.56	-0.86	-0.04

Competitive Comparison of Nektar Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Nektar Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nektar Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's EV-to-Revenue falls into.

Nektar Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Nektar Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	135.360	/	83.355
	=	1.62

Nektar Therapeutics's current Enterprise Value is €135.36 Mil.
Nektar Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €83.36 Mil.

Nektar Therapeutics (FRA:ITH) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Nektar Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.59	/	0.436
	=	3.65

Nektar Therapeutics's share price for today is €1.59.
Nektar Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.44.

Nektar Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics (FRA:ITH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (FRA:ITH) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

NKTR:USA

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Nektar Therapeutics (FRA:ITH) Headlines

No Headlines